Literature DB >> 19774429

Proton pump inhibitors in the management of GERD.

Philip O Katz1, Stacey Zavala.   

Abstract

INTRODUCTION: Management of gastroesophageal reflux disease (GERD) is based on the concept that gastric contents, principally acid and pepsin, are responsible for symptoms of reflux and esophageal injury. Pharmacologic treatment is based on the principle that controlling intragastric pH will affect esophageal healing and subsequently symptom relief. RESULTS AND DISCUSSION: Control of pH can be accomplished with antisecretory agents, principally proton pump inhibitors (PPIs). The majority of patients respond to a single daily dose of a PPI; however, some will require higher doses, and a small percentage are "refractory" to twice daily dosing of these drugs. The success of these agents, and in fact the reasons for "failure," is elucidated by understanding the mechanism of action of PPIs and the effect of dose timing and meals on their efficacy.
CONCLUSION: Awareness of new concerns regarding potential side effects of PPIs when used long-term require careful thought as GERD is a chronic disease with most needing some form of medical treatment over time. This article reviews the pharmacologic properties of PPIs and the impact on the treatment of GERD.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19774429     DOI: 10.1007/s11605-009-1015-3

Source DB:  PubMed          Journal:  J Gastrointest Surg        ISSN: 1091-255X            Impact factor:   3.452


  27 in total

1.  Proton pump inhibitors: better acid suppression when taken before a meal than without a meal.

Authors:  J G Hatlebakk; P O Katz; L Camacho-Lobato; D O Castell
Journal:  Aliment Pharmacol Ther       Date:  2000-10       Impact factor: 8.171

2.  Prevalence and clinical spectrum of gastroesophageal reflux: a population-based study in Olmsted County, Minnesota.

Authors:  G R Locke; N J Talley; S L Fett; A R Zinsmeister; L J Melton
Journal:  Gastroenterology       Date:  1997-05       Impact factor: 22.682

Review 3.  Omeprazole.

Authors:  P N Maton
Journal:  N Engl J Med       Date:  1991-04-04       Impact factor: 91.245

4.  Comparison of the effects of immediate-release omeprazole oral suspension, delayed-release lansoprazole capsules and delayed-release esomeprazole capsules on nocturnal gastric acidity after bedtime dosing in patients with night-time GERD symptoms.

Authors:  P O Katz; F K Koch; E D Ballard; R G Bagin; T C Gautille; G C Checani; D L Hogan; V S V Pratha
Journal:  Aliment Pharmacol Ther       Date:  2007-01-15       Impact factor: 8.171

5.  Use of gastric acid-suppressive agents and the risk of community-acquired Clostridium difficile-associated disease.

Authors:  Sandra Dial; J A C Delaney; Alan N Barkun; Samy Suissa
Journal:  JAMA       Date:  2005-12-21       Impact factor: 56.272

6.  Long-term omeprazole treatment in resistant gastroesophageal reflux disease: efficacy, safety, and influence on gastric mucosa.

Authors:  E C Klinkenberg-Knol; F Nelis; J Dent; P Snel; B Mitchell; P Prichard; D Lloyd; N Havu; M H Frame; J Romàn; A Walan
Journal:  Gastroenterology       Date:  2000-04       Impact factor: 22.682

7.  Relationship between intragastric acid control and healing status in the treatment of moderate to severe erosive oesophagitis.

Authors:  P O Katz; G G Ginsberg; P E Hoyle; M B Sostek; J T Monyak; D G Silberg
Journal:  Aliment Pharmacol Ther       Date:  2007-03-01       Impact factor: 8.171

8.  Esomeprazole (40 mg) compared with lansoprazole (30 mg) in the treatment of erosive esophagitis.

Authors:  Donald O Castell; Peter J Kahrilas; Joel E Richter; Nimish B Vakil; David A Johnson; Seth Zuckerman; Wendy Skammer; Jeffrey G Levine
Journal:  Am J Gastroenterol       Date:  2002-03       Impact factor: 10.864

Review 9.  Extraesophageal gastroesophageal reflux disease. Presentations and approach to treatment.

Authors:  M B Fennerty
Journal:  Gastroenterol Clin North Am       Date:  1999-12       Impact factor: 3.806

Review 10.  Pharmacological management of gastro-oesophageal reflux disease.

Authors:  E C Klinkenberg-Knol; H P Festen; S G Meuwissen
Journal:  Drugs       Date:  1995-05       Impact factor: 9.546

View more
  19 in total

Review 1.  Update in procedural therapy for GERD--magnetic sphincter augmentation, endoscopic transoral incisionless fundoplication vs laparoscopic Nissen fundoplication.

Authors:  Michael X Min; Robert A Ganz
Journal:  Curr Gastroenterol Rep       Date:  2014-02

2.  Is Toupet fundoplication the procedure of choice for treating gastroesophageal reflux disease? Results of a prospective randomized experimental trial comparing three major antireflux operations in a porcine model.

Authors:  K Bachmann; R Wachowiak; C Rempf; Y Vashist; O Mann; E F Yekebas; J R Izbicki; K A Gawad
Journal:  Surg Endosc       Date:  2011-05-14       Impact factor: 4.584

Review 3.  From Heartburn to Barrett's Esophagus, and Beyond.

Authors:  Francisco Schlottmann; Marco G Patti; Nicholas J Shaheen
Journal:  World J Surg       Date:  2017-07       Impact factor: 3.352

Review 4.  Antireflux surgery for dysplastic Barrett.

Authors:  Marco E Allaix; Marco G Patti
Journal:  World J Surg       Date:  2015-03       Impact factor: 3.352

Review 5.  Update on novel endoscopic therapies to treat gastroesophageal reflux disease: A review.

Authors:  Jessica Hopkins; Noah J Switzer; Shahzeer Karmali
Journal:  World J Gastrointest Endosc       Date:  2015-08-25

6.  Magnetic sphincter augmentation and fundoplication for GERD in clinical practice: one-year results of a multicenter, prospective observational study.

Authors:  Martin Riegler; Sebastian F Schoppman; Luigi Bonavina; David Ashton; Thomas Horbach; Matthias Kemen
Journal:  Surg Endosc       Date:  2014-08-30       Impact factor: 4.584

Review 7.  Medical versus surgical treatment for refractory or recurrent peptic ulcer.

Authors:  Kurinchi Selvan Gurusamy; Elena Pallari
Journal:  Cochrane Database Syst Rev       Date:  2016-03-29

8.  Should peri-gastrectomy gastric acidity be our focus among gastric cancer patients?

Authors:  Lei Huang; A-Man Xu; Tuan-Jie Li; Wen-Xiu Han; Jing Xu
Journal:  World J Gastroenterol       Date:  2014-06-14       Impact factor: 5.742

9.  Multi-institutional outcomes using magnetic sphincter augmentation versus Nissen fundoplication for chronic gastroesophageal reflux disease.

Authors:  Heather F Warren; Jessica L Reynolds; John C Lipham; Joerg Zehetner; Nikolai A Bildzukewicz; Paul A Taiganides; Jody Mickley; Ralph W Aye; Alexander S Farivar; Brian E Louie
Journal:  Surg Endosc       Date:  2015-11-05       Impact factor: 4.584

Review 10.  Laparoscopic fundoplication surgery versus medical management for gastro-oesophageal reflux disease (GORD) in adults.

Authors:  Sushil K Garg; Kurinchi Selvan Gurusamy
Journal:  Cochrane Database Syst Rev       Date:  2015-11-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.